Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05327491 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 146
- Enrollment target
NCT05327491 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 146 participants.
The verdict
NCT05327491, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 146 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the pharmacokinetics (PK) of sotorasib administered orally as 1 tablet under fasted conditions to sotorasib administered orally as 2 tablets under fasted conditions.
Interventions
- DRUG Sotorasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2022-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05327491
The ClinicalTrials.gov registry entry for NCT05327491 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sotorasib is the first listed.
NCT05327491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05327491 about?
NCT05327491 is a clinical study titled "A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets". The primary objective of the study is to compare the pharmacokinetics (PK) of sotorasib administered orally as 1 tablet under fasted conditions to sotorasib administered orally as 2 tablets under fasted conditions.
What is the current status of trial NCT05327491?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 146 participants. The study started on 2022-03-21. Estimated completion is 2022-07-17.
What interventions are being tested in trial NCT05327491?
The interventions under investigation include: Sotorasib (DRUG).
Who is sponsoring clinical trial NCT05327491?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.